Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA To Issue Remarketer Labeling Regs, Monitor Registration System

This article was originally published in The Gray Sheet

Executive Summary

Device remarketers that label serviced devices as "ready for clinical use" under a recently proposed voluntary registration system will be subject to FDA enforcement action if the devices do not meet performance specifications, according to FDA staffers.

You may also be interested in...



FDA Reuse Policy Demands Data From Both OEMs And Reprocessors

FDA's revised policy on reprocessing of disposable medical devices would require manufacturers seeking to label a product as single-use only to submit data demonstrating that it cannot adequately be reprocessed, FDA staffers report.

Extensive Labeling Required Under Device Remarketers' Voluntary System

Device remarketers and servicers should indicate whether reserviced devices are "ready for clinical use" or "must be checked for proper performance and safety" under a proposed voluntary registration system issued Sept. 9 by an industry task force coordinated by the Association for the Advancement of Medical Instrumentation.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel